Covid-19 testing concept stock Guangzhou Wondfo Biotech Co.Ltd(300482) with a total market value of more than 20 billion yuan announced that it achieved a net profit of 904 million yuan in the first quarter of 2022, with a year-on-year increase of 481.32% . The company’s covid-19 series testing reagents have been sold in more than 100 countries and regions in Europe, Asia, Latin America and the Middle East. The covid-19 testing business has made a significant contribution to the growth of performance .
From the operating performance of the company, Guangzhou Wondfo Biotech Co.Ltd(300482) made a net profit of 904 million yuan in the first quarter, exceeding the net profit of last year (634 million) , with an increase of more than 40% single quarter on quarter, net profit increased by more than 124 times meanwhile, single quarter net profit after the second quarter of last year hit a record high with an increase of 122%.
As soon as the announcement was made, investors had a heated discussion. Some investors thought that the price limit would be increased by one word tomorrow, while others thought that the performance was lower than expected.
For a longer time, Guangzhou Wondfo Biotech Co.Ltd(300482) from the low point in January 2019 to the record high in July 2020, the cumulative maximum increase in the stock price reached 383%. However, the subsequent high-level correction was also very tragic. So far, the highest decline of has exceeded 60% .
According to public information, Guangzhou Wondfo Biotech Co.Ltd(300482) main business is in vitro diagnosis, with revenue accounting for more than 90%. By product, the total revenue of infectious disease and chronic disease detection accounted for 76.87%. Among them, covid-19 series testing reagents achieved a sales revenue of about 1.045 billion yuan in 2021, accounting for more than 37% of the company’s total revenue .
Last month, Guangzhou Wondfo Biotech Co.Ltd(300482) covid-19 antigen detection kit was officially included in China’s first listing list .
Huatai Securities Co.Ltd(601688) Dai Wen and other analysts said in the Research Report on March 13 that covid-19 antigen detection, as a supplementary means of routine nucleic acid detection, can effectively improve the ability of early diagnosis in the screening scenario of specific populations Guangzhou Wondfo Biotech Co.Ltd(300482) covid-19 antigen detection kit will become a powerful supplement to nucleic acid detection and is expected to bring new growth momentum .
Benefiting from the growth of overseas sales of covid-19 antigen detection kit products, covid-19 detection leading stock Andon Health Co.Ltd(002432) previously announced that first quarter net profit is expected to be 14 billion yuan to 16 billion yuan, a year-on-year increase of 367 times to 419 times
